Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesNewsCalendarCompanyFinancialsRevisions 
Financials (EUR)
Sales 2018 94,0 M
EBIT 2018 -9,76 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 177 M
EBIT 2019 45,6 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 37,2x
Capi. / Sales2019 19,8x
Capitalization 3 498 M
More Financials
Company
Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.It includes hematology, inflammation, infectious disease, autoimmune disease, oncology, and immuno-oncology.The company was founded on July... 
More about the company
Latest news on ABLYNX
07/10ACCELERON PHARMA : Appoints Robert K. Zeldin, M.D., Chief Medical Officer
AQ
07/06SANOFI : - CHMP recommends approval of Cablivi
AQ
06/30Sanofi, Advent finally shake hands on $2.2B European generics sale
AQ
06/29ABLYNX : `Rapidly evolving` biotech company to create 10 jobs at York Science Pa..
AQ
06/29SANOFI : CHMP Recommends Approval of Cablivi (Caplacizumab)
AQ
06/22SANOFI : completes its acquisition of Ablynx following the expiration of the Squ..
AQ
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
06/19ABLYNX : Sanofi completes its acquitision of ablynx following the expiration of ..
GL
05/29ABLYNX : Crossing thresholds
CO
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/02YOUR DAILY PHARMA SCOOP : KPTI Data, Allergan Write-Off, Celgene Down On Delay 
04/30Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV 
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
Income Statement Evolution
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert Freisen Chief Scientific Officer
Remi Vermeiren Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX117.28%0
CELLTRION, INC.--.--%32 830
IQVIA HOLDINGS INC12.03%22 488
LONZA GROUP9.38%21 400
INCYTE CORPORATION-25.70%14 887
SEATTLE GENETICS, INC.27.16%10 750